MELACAN™
Targets 52 key genes in melanoma
Melanoma is the most serious type of skin cancer. Treatment for melanoma depends on the size and stage of cancer. While surgical removal may be adequate for early-stage small melanomas, when it spread beyond the skin, chemotherapy, radiation therapy, targeted therapy or immunotherapy may be needed. To date, multiple targeted therapies (e.g. BRAF and MEK inhibitors) and immunotherapies (e.g. PD-1 and CTLA-4 inhibitors) have been approved by FDA to treat advanced melanoma.
- Detects driver mutations in melanoma such as BRAF, MEK, c-KIT and NRAS to inform targeted therapy options
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Assesses genetic predisposition for melanoma
WHO IS IT FOR
- Melanoma patients seeking precision medicine
- Patients with unresectable or metastatic melanoma
- Melanoma patients with recurrent disease
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
Liquid biopsy (plasma and others)
THYROCAN™
Targets 54 key genes in thyroid cancer
Thyroid cancer develops from the thyroid gland. Although thyroid cancers are curable with treatments such as surgery, hormone therapy, radioactive iodine and the most common types of thyroid cancer, papillary and follicular subtypes by external radiation therapy. One-tenth of such patients will have recurrent disease.
However, medullary thyroid cancer has a worse prognosis and may also be genetically inherited. Anaplastic thyroid cancer is the most aggressive form of thyroid cancer. Several targeted therapies with kinase inhibitors have been approved to treat non-responsive radioactive iodine patients with differentiated papillary and follicular thyroid cancers as well as medullary and anaplastic thyroid cancer patients.
- Detects driver mutations in thyroid cancer such as BRAF, RET and RAS to inform targeted therapy options
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Assesses genetic predisposition for thyroid cancer
WHO IS IT FOR
- Thyroid cancer patients seeking precision medicine
- Differentiated papillary and follicular thyroid cancer patients resistant to radioactive iodine therapy
- Medullary and anaplastic thyroid cancer patients
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
Liquid biopsy (plasma and others)
RETINOBLASTOMA GENETIC TESTING
Identify genetic predispositions fast
Retinoblastoma (RB) is a cancer that originates in the retina and affects young children in one (unilateral, ~60%) or both (bilateral, ~40%) eyes. It is mostly caused by RB1 gene mutations and the RB1 mutation can be inherited from one parent (~10%). Individuals that inherit RB1 mutation on one copy of the RB1 gene is predisposed to RB and other cancers later in the life when the second RB1 gene is also damaged in the tumor.
The majority of RB (~90%) develops spontaneously pre-conception or during early development of the fetus and is not heritable to future offspring. Therefore, RB1 genetic testing is critical for RB patients to assess the likelihood of developing additional tumors in the eye, to monitor the spread of cancer and improve surveillance and treatment of family members.
- Analyzes mutations in 27 exons, splicing sites flanking the exons and key promoter region of RB1 gene at germline, somatic and mosaic level
- Detects whole gene or exon-level copy number variation (CNV) of RB1 gene
- Optional validation test for family members of proband
WHO IS IT FOR
- Patients with unilateral or bilateral RB
- Parents of RB patients with confirmed RB1 mutation
- Individuals with one or more immediate family members with RB
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Peripheral blood
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.